Stockscreener 앱 받기
46.07
6.87%
-3.40
시장 영업 전:
46.77
0.70
+1.52%
Celcuity Inc 주식(CELC)의 최신 뉴스
Celcuity (NASDAQ:CELC) Stock Price Down 5.1%What's Next? - MarketBeat
Historical volatility pattern of Celcuity Inc. visualizedJuly 2025 PostEarnings & Weekly Market Pulse Alerts - newser.com
Celcuity's (CELC) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Celcuity: Blink And You Missed It (NASDAQ:CELC) - Seeking Alpha
Celcuity's VIKTORIA-1 Results To Anchor ESMO Presentation; NDA Submission Underway - RTTNews
Short interest data insights for Celcuity Inc.Quarterly Investment Review & Weekly Watchlist of Top Performers - newser.com
What data driven models say about Celcuity Inc.’s futureTrade Exit Report & Safe Capital Growth Tips - newser.com
Multi asset correlation models including Celcuity Inc.Weekly Loss Report & Weekly Sector Rotation Insights - newser.com
Celcuity Inc. stock trend forecastStop Loss & Daily Stock Trend Reports - newser.com
Long term hold vs stop loss in Celcuity Inc.Layoff News & Daily Growth Stock Investment Tips - newser.com
Can technical indicators confirm Celcuity Inc.’s reversal2025 Trade Ideas & Daily Oversold Stock Bounce Ideas - newser.com
Should FDA Real-Time Review of Gedatolisib Prompt a Closer Look From Celcuity (CELC) Investors? - simplywall.st
Needham Maintains Celcuity(CELC.US) With Buy Rating, Maintains Target Price $70 - 富途牛牛
Celcuity (NASDAQ:CELC) Given Buy Rating at Needham & Company LLC - MarketBeat
How to interpret RSI for Celcuity Inc. stock2025 Institutional Moves & Daily Stock Momentum Reports - newser.com
Celcuity (CELC): Valuing the Stock After FDA Acceptance of Gedatolisib and Major Pipeline Progress - Sahm
Celcuity Expands Credit Facility to $500 Million - MSN
Why Celcuity Inc. stock appeals to dividend seekers2025 Technical Overview & Smart Investment Allocation Insights - newser.com
Celcuity (NASDAQ:CELC) Shares Down 4.8%Here's Why - MarketBeat
3 Growth Companies With High Insider Ownership Seeing Up To 63% Revenue Growth - simplywall.st
Celcuity Inc. (CELC)’s FDA NDA for Gedatolisib Accepted Under RTOR, Accelerating Review - Insider Monkey
Certain Options of Celcuity Inc. are subject to a Lock-Up Agreement Ending on 29-SEP-2025. - MarketScreener
Certain Pre-Funded Warrants of Celcuity Inc. are subject to a Lock-Up Agreement Ending on 29-SEP-2025. - MarketScreener
Certain Common Stock of Celcuity Inc. are subject to a Lock-Up Agreement Ending on 29-SEP-2025. - MarketScreener
Craig-Hallum Remains a Buy on Celcuity (CELC) - The Globe and Mail
The Bull Case For Celcuity (CELC) Could Change Following Expanded Credit Facility and Rising Commercial Ambitions - simplywall.st
Celcuity (NASDAQ:CELC) Shares Down 5.5%Time to Sell? - MarketBeat
Celcuity to present phase 3 breast cancer trial data at ESMO congress - Investing.com Nigeria
Goldman Sachs Group Inc. Sells 28,686 Shares of Celcuity, Inc. $CELC - MarketBeat
Guggenheim initiates Celcuity stock with Buy rating on breast cancer drug potential By Investing.com - Investing.com South Africa
Guggenheim initiates Celcuity stock with Buy rating on breast cancer drug potential - Investing.com Australia
Guggenheim Maintains Celcuity(CELC.US) With Buy Rating, Raises Target Price to $110 - 富途牛牛
5.74%
자본화:
|
볼륨(24시간):